Exploratory Study of Mavacamten (MYK-461) in Patients with

Build status - In Progress

Recruiting

18 years - 99 years

All

Phase 2

5 participants needed

1 Location

Brief description of study

The purpose of this study is to compare the effect of the investigational drug, mavacamten, (MYK-461), to a placebo (an inactive substance) in patients with Non-obstructive Hypertrophic Cardiomyopathy (nHCM).

Detailed description of study

This study is being done to test whether mavacamten is safe, and can be tolerated in nHCM and to study whether it helps to improve symptoms or ability to exercise.
Mavacamten is an investigational drug. This means that it has not been approved by the Food and Drug Administration (FDA) or any regulatory agency for routine clinical use, including the treatment of nHCM.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: cardiomyopathy,nHCM
Age: 18 years - 99 years
Gender: All

Updated on 04 Aug 2024. Study ID: 829315

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

View email

Phone

View phone

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.